Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 15/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | IDH1 | O75874 | 1/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5648266 | 0.99 | F2 (0.50) | F2PRSS1RECQLPOLBHPGD | |
| SCHEMBL5650427 | 0.91 | F2 (0.44) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL5650960 | 0.90 | F2 (0.49) | F2RECQLPOLBHPGDIDH1 | |
| SCHEMBL5647188 | 0.89 | KLKB1 (0.50) | F2PRSS1RECQL | |
| SCHEMBL5969043 | 0.89 | F2 (0.47) | F2RECQLPOLBHPGDP2RX7 | |
| Hydrochloric Acid SCHEMBL5650396 | 0.87 | F2 (0.56) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL5650295 | 0.86 | F2 (0.48) | F2PRSS1P2RX7PRSS2PRSS3 | |
| SCHEMBL5647493 | 0.85 | F2 (0.40) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL5650692 | 0.85 | F2 (0.51) | F2POLBHPGDIDH1 | |
| SCHEMBL5653556 | 0.85 | F2 (0.43) | F2RECQLPOLBHPGDP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070161643-A1 | Pyridin-2-one compounds useful as inhibitors of thrombin | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161643-A1 | Pyridin-2-one compounds useful as inhibitors of thrombin | PLG, F2, PLAT | F2 2/4885PRSS1 20/4885RECQL 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.